|
1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ran Q, Wadhwa R, Kawai R, Kaul SC, Sifers
RN, Bick RJ, Smith JR and Pereira-Smith OM: Extramitochondrial
localization of mortalin/mthsp70/PBP74/GRP75. Biochem Biophys Res
Commun. 275:174–179. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wadhwa R, Yaguchi T, Hasan MK, Mitsui Y,
Reddel RR and Kaul SC: Hsp70 family member, mot-2/mthsp70/GRP75,
binds to the cytoplasmic sequestration domain of the p53 protein.
Exp Cell Res. 274:246–253. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dundas SR, Lawrie LC, Rooney PH and Murray
GI: Mortalin is over-expressed by colorectal adenocarcinomas and
correlates with poor survival. J Pathol. 205:74–81. 2005.
View Article : Google Scholar
|
|
5
|
Takano S, Wadhwa R, Yoshii Y, Nose T, Kaul
SC and Mitsui Y: Elevated levels of mortalin expression in human
brain tumors. Exp Cell Res. 237:38–45. 1997. View Article : Google Scholar
|
|
6
|
Ando K, Oki E, Zhao Y, Ikawa-Yoshida A,
Kitao H, Saeki H, Kimura Y, Ida S, Morita M, Kusumoto T, et al:
Mortalin is a prognostic factor of gastric cancer with normal p53
function. Gastric Cancer. 17:255–262. 2014. View Article : Google Scholar
|
|
7
|
Wadhwa R, Takano S, Kaur K, Deocaris CC,
Pereira-Smith OM, Reddel RR and Kaul SC: Upregulation of
mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J
Cancer. 118:2973–2980. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rozenberg P, Kocsis J, Saar M, Prohászka
Z, Füst G and Fishelson Z: Elevated levels of mitochondrial
mortalin and cytosolic HSP70 in blood as risk factors in patients
with colorectal cancer. Int J Cancer. 133:514–518. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jubran R, Kocsis J, Garam N, Maláti É,
Gombos T, Barabás L, Gráf L, Prohászka Z and Fishelson Z:
Circulating mitochondrial stress 70 protein/mortalin and cytosolic
Hsp70 in blood: Risk indicators in colorectal cancer. Int J Cancer.
141:2329–2335. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kaul SC, Deocaris CC and Wadhwa R: Three
faces of mortalin: A housekeeper, guardian and killer. Exp
Gerontol. 42:263–274. 2007. View Article : Google Scholar
|
|
11
|
Voisine C, Craig EA, Zufall N, von Ahsen
O, Pfanner N and Voos W: The protein import motor of mitochondria:
Unfolding and trapping of preproteins are distinct and separable
functions of matrix Hsp70. Cell. 97:565–574. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pilzer D and Fishelson Z: Mortalin/GRP75
promotes release of membrane vesicles from immune attacked cells
and protection from complement-mediated lysis. Int Immunol.
17:1239–1248. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pilzer D, Saar M, Koya K and Fishelson Z:
Mortalin inhibitors sensitize K562 leukemia cells to
complement-dependent cytotoxicity. Int J Cancer. 126:1428–1435.
2010.
|
|
14
|
Saar Ray M, Moskovich O, Iosefson O and
Fishelson Z: Mortalin/GRP75 binds to complement C9 and plays a role
in resistance to complement-dependent cytotoxicity. J Biol Chem.
289:15014–15022. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Frankel AD and Pabo CO: Cellular uptake of
the tat protein from human immunodeficiency virus. Cell.
55:1189–1193. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raucher D and Ryu JS: Cell-penetrating
peptides: Strategies for anticancer treatment. Trends Mol Med.
21:560–570. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Darzynkiewicz Z, Juan G and Bedner E:
Determining cell cycle stages by flow cytometry. Curr Protoc Cell
Biol Chapter. 8(Unit 8): 42001.
|
|
18
|
Smiley ST, Reers M, Mottola-Hartshorn C,
Lin M, Chen A, Smith TW, Steele GD Jr and Chen LB: Intracellular
heterogeneity in mito-chondrial membrane potentials revealed by a
J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA.
88:3671–3675. 1991. View Article : Google Scholar
|
|
19
|
Vivès E, Brodin P and Lebleu B: A
truncated HIV-1 Tat protein basic domain rapidly translocates
through the plasma membrane and accumulates in the cell nucleus. J
Biol Chem. 272:16010–16017. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nagata S: Apoptosis and Clearance of
Apoptotic Cells. Annu Rev Immunol. 36:489–517. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hirt UA and Leist M: Rapid,
noninflammatory and PS-dependent phagocytic clearance of necrotic
cells. Cell Death Differ. 10:1156–1164. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Caserta TM, Smith AN, Gultice AD, Reedy MA
and Brown TL: Q-VD-OPh, a broad spectrum caspase inhibitor with
potent antiapoptotic properties. Apoptosis. 8:345–352. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhivotovsky B and Orrenius S: Calcium and
cell death mechanisms: A perspective from the cell death community.
Cell Calcium. 50:211–221. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mason AJ, Marquette A and Bechinger B:
Zwitterionic phospholipids and sterols modulate antimicrobial
peptide-induced membrane destabilization. Biophys J. 93:4289–4299.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Prenner EJ, Lewis RNAH, Jelokhani-Niaraki
M, Hodges RS and McElhaney RN: Cholesterol attenuates the
interaction of the antimicrobial peptide gramicidin S with
phospholipid bilayer membranes. Biochim Biophys Acta. 1510:83–92.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Moskovich O, Herzog LO, Ehrlich M and
Fishelson Z: Caveolin-1 and dynamin-2 are essential for removal of
the complement C5b-9 complex via endocytosis. J Biol Chem.
287:19904–19915. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Y, Liu W, Song XD and Zuo J: Effect of
GRP75/mthsp70/PBP74/mortalin overexpression on intracellular ATP
level, mitochondrial membrane potential and ROS accumulation
following glucose deprivation in PC12 cells. Mol Cell Biochem.
268:45–51. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun SY: N-acetylcysteine, reactive oxygen
species and beyond. Cancer Biol Ther. 9:109–110. 2010. View Article : Google Scholar
|
|
29
|
Moskovich O and Fishelson Z:
Quantification of complement C5b-9 binding to cells by flow
cytometry. The Complement System: Methods and Protocols. 1100th
edition. Gadjeva M: Humana Press; Totowa, NJ: pp. 103–108. 2014,
View Article : Google Scholar
|
|
30
|
Bhakdi S, Tranum-Jensen J and Klump O: The
terminal membrane C5b-9 complex of human complement. Evidence for
the existence of multiple protease-resistant polypeptides that form
the trans-membrane complement channel. J Immunol. 124:2451–2457.
1980.PubMed/NCBI
|
|
31
|
Koya K, Li Y, Wang H, Ukai T, Tatsuta N,
Kawakami M, Shishido and Chen LB: MKT-077, a novel rhodacyanine dye
in clinical trials, exhibits anticarcinoma activity in preclinical
studies based on selective mitochondrial accumulation. Cancer Res.
56:538–543. 1996.PubMed/NCBI
|
|
32
|
Kunzelmann-Marche C, Freyssinet JM and
Martínez MC: Regulation of phosphatidylserine transbilayer
redistribution by store-operated Ca2+ entry: Role of actin
cytoskeleton. J Biol Chem. 276:5134–5139. 2001. View Article : Google Scholar
|
|
33
|
Heuck AP, Moe PC and Johnson BB: The
cholesterol-dependent cytolysin family of gram-positive bacterial
toxins. Subcell Biochem. 51:551–577. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Won A, Ruscito A and Ianoul A: Imaging the
membrane lytic activity of bioactive peptide latarcin 2a. Biochim
Biophys Acta. 1818:3072–3080. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Del Gaizo V, MacKenzie JA and Payne RM:
Targeting proteins to mitochondria using TAT. Mol Genet Metab.
80:170–180. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Palmer AC and Sorger PK: Combination
cancer therapy can confer benefit via patient-topatient variability
without drug additivity or synergy. Cell. 171:1678–1691.e13. 2017.
View Article : Google Scholar
|
|
37
|
Foucquier J and Guedj M: Analysis of drug
combinations: Current methodological landscape. Pharmacol Res
Perspect. 3:e001492015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kurrikoff K, Aphkhazava D and Langel Ü:
The future of peptides in cancer treatment. Curr Opin Pharmacol.
47:27–32. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Guidotti G, Brambilla L and Rossi D:
Peptides in clinical development for the treatment of brain tumors.
Curr Opin Pharmacol. 47:102–109. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bayat Mokhtari R, Homayouni TS, Baluch N,
Morgatskaya E, Kumar S, Das B and Yeger H: Combination therapy in
combating cancer. Oncotarget. 8:38022–38043. 2017. View Article : Google Scholar : PubMed/NCBI
|
